TTI:CA:TSV-Thiogenesis Therapeutics Corp. (CAD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.68

Change

0.00 (0.00)%

Market Cap

USD 0.03B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

N/A

USD 0.19B
ARCH:CA Arch Biopartners Inc

N/A

USD 0.12B
COV:CA Covalon Technologies Ltd.

N/A

USD 0.08B
MIR:CA MedMira Inc

N/A

USD 0.06B
NRX:CA NurExone Biologic Inc.

N/A

USD 0.04B
GSD:CA Devonian Health Group Inc

N/A

USD 0.02B
KNE:CA Kane Biotech Inc

N/A

USD 0.02B
SBM:CA Sirona Biochem Corp

N/A

USD 0.02B
HEM:CA Hemostemix Inc

N/A

USD 8.28M
RKV:CA Rakovina Therapeutics Inc

N/A

USD 7.67M

ETFs Containing TTI:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.33% 24% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.33% 24% F 46% F
Trailing 12 Months  
Capital Gain -12.82% 13% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.82% 13% F 45% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 15.76% N/A N/A 65% D
Dividend Return 15.76% N/A N/A 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 20.54% N/A N/A 93% A
Risk Adjusted Return 76.72% N/A N/A 99% N/A
Market Capitalization 0.03B 72% C 76% C+

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector